Welcome to our dedicated page for Steris Plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for STERIS plc (NYSE: STE) provide detailed regulatory information about this Ireland-incorporated medical technology company, which focuses on products and services that support patient care with an emphasis on infection prevention. Through its filings, STERIS discloses financial results, governance decisions, executive transitions and shareholder meeting outcomes, giving investors a structured view of the company’s regulatory history.
Current reports on Form 8-K filed by STERIS include items on Results of Operations and Financial Condition, where the company furnishes press releases announcing quarterly financial results. These filings reference segment performance for Healthcare, Applied Sterilization Technologies (AST) and Life Sciences, and describe the use of non-GAAP measures such as adjusted net income, adjusted earnings per diluted share, free cash flow, organic revenue growth and constant currency organic revenue growth.
Other 8-K filings address Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, detailing transitions in the Chief Financial Officer role and related compensation and equity arrangements. Filings also summarize matters submitted to a vote of security holders, including the election of directors, appointment and remuneration of auditors, advisory votes on executive compensation and renewals of the Board’s authority to issue shares and opt out of statutory pre-emption rights under Irish law.
On this page, investors can review STERIS’s SEC reports alongside AI-powered summaries that explain the key points of each filing, highlight important sections and clarify technical language. Real-time updates from EDGAR ensure that new Forms 8-K and other reports appear promptly. Users can quickly identify filings related to quarterly earnings (such as 8-Ks furnishing press releases), governance and compensation topics, and other material events that shape STERIS’s financial and corporate profile.
Alegria Esther M., a director of STERIS plc (STE), reported equity awards on Form 4 dated 08/08/2025. The filing shows an acquisition of 1,407 nonqualified stock options at an exercise price of $242.85 and 487 Career Restricted Stock Units (RSUs). The filing states the options are fully vested and exercisable immediately and carry an expiration date of 08/08/2035. Each Career RSU represents the right to one ordinary share and is fully vested but will be settled in shares six months after the director ceases Board service. The Form reports total beneficial ownership following these transactions of 2,896 ordinary shares and was signed by an authorized representative on 08/12/2025.
Karen L. Burton, VP & CAO and a company officer of STERIS plc (STE), reported a sale and an outstanding option in a Form 4 filing. On 08/11/2025 she sold 7,900 ordinary shares at a weighted average price of $241.73 per share (sales ranged from $241.33 to $242.32), reducing her direct beneficial ownership to 5,994 ordinary shares.
She continues to hold a fully vested employee stock option to purchase 7,900 ordinary shares at a strike price of $114.22 that originated from the company’s March 2019 redomiciliation exchange. Of the remaining shares, 3,216 are restricted and vest in scheduled tranches between October 1, 2025 and June 5, 2028.
Form 144 notice for STERIS plc (STE) shows a proposed sale of 3,781 ordinary shares executed through Charles Schwab with an aggregate market value of $914,084 and listing the shares outstanding as 98,490,606. The table indicates the shares were acquired and disposed on 08/12/2025 through an employee stock option exercise with the payment described as a broker payment for a cashless exercise. The filing also discloses a prior sale during the past three months: 4,110 shares sold on 08/11/2025 for $993,562. The notice includes the broker name and exchange (Charles Schwab & Co.; NYSE) and the mandatory representation that the seller is not aware of undisclosed material adverse information.
STERIS plc (STE) filed a Form 144 reporting a proposed sale of 4,110 ordinary shares through Charles Schwab & Co., Inc., with an aggregate market value of $993,562.00 and an approximate sale date of 08/11/2025. The filing shows the securities were acquired on 08/11/2025 via an employee stock option exercise and the payment was made through a broker cashless exercise.
The table lists the issuer's shares outstanding as 98,490,606. The filing also states there were no securities sold in the past three months by the person for whose account these securities are to be sold and includes the standard attestation that the filer is not aware of undisclosed material adverse information.
STERIS plc filed a Form 144 reporting a proposed sale of 4,110 ordinary shares to be executed on 08/11/2025 through Charles Schwab & Co., Inc. The filing lists an aggregate market value of $994,450 and shows 98,490,606 shares outstanding. The shares were acquired on 08/11/2025 via an employee stock option exercise and the payment method is recorded as a broker payment for a cashless exercise.
The notice states no securities were sold by the person in the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
STERIS plc filed a Form 144 reporting a proposed sale of 3,495 ordinary shares with an aggregate market value of $844,249, to be sold on the NYSE through Charles Schwab on 08/11/2025. The shares were acquired on 08/11/2025 via an employee stock option exercise and payment was completed through a broker cashless exercise. The filing reports 98,490,606 shares outstanding and states Nothing to Report for securities sold in the past three months. The filing does not identify the person for whose account the securities are to be sold.
STERIS plc reported a Form 144 notice for an insider sale of ordinary shares. The filing shows 7,900 shares offered through Charles Schwab & Co., with an aggregate market value of $1,909,646.00 and 98,490,606 shares outstanding for the company. The shares were acquired and are to be sold on 08/11/2025 via an employee stock option exercise using a broker payment for a cashless exercise.
The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer. Relationship to the issuer and the identity of the selling person are not specified in the visible fields.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
